Qaasid News

Download Our App

Category: 3. Business

  • Transcriptomic profiles of endocrine-resistant breast cancer | BMC Cancer

    Transcriptomic profiles of endocrine-resistant breast cancer | BMC Cancer

  • Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.

    PubMed 

    Google Scholar 

  • Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 2021; 32: 1216–1235.

  • Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159–82.

    CAS 
    PubMed 

    Google Scholar 

  • Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

    CAS 
    PubMed 

    Google Scholar 

  • Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.

    Google Scholar 

  • Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26-35.

    PubMed 

    Google Scholar 

  • Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34.

    CAS 
    PubMed 

    Google Scholar 

  • Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–21.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Confederation of Regional Cancer Centres in Sweden. National Clinical Cancer Care Guidelines Breast Cancer. 2024. https://kunskapsbanken.cancercentrum.se/globalassets/cancerdiagnoser/brost/vardprogram/nationellt-vardprogram-brostcancer.pdf (Accessed 24 Oct 2024).

  • Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321:288–300.

    CAS 
    PubMed 

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386: 1341–1352.

  • Herzog SK, Fuqua SAW. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer. 2022;126:174–86.

    CAS 
    PubMed 

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol 2022; 23: 382–392.

  • Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388:2058–70.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Bidard F-C, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246–56.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Makhlin I, Fallowfield L, Henry NL, Burstein HJ, Somerfield MR, DeMichele A. Targeted therapies, sequencing strategies, and beyond in metastatic hormone receptor-positive breast cancer: ASCO guideline clinical insights. JCO Oncol Pract 2024; : OP2400547.

  • AlFakeeh A, Brezden-Masley C. Overcoming endocrine resistance in hormone receptor-positive breast cancer. Curr Oncol. 2018;25:S18–27.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771–784.

  • Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377:1836–46.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–1717.

  • Miranda F, Prazeres H, Mendes F, Martins D, Schmitt F. Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers. Mol Biol Rep. 2022;49:717–33.

    CAS 
    PubMed 

    Google Scholar 

  • Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer–An overview and update. Mol Cell Endocrinol. 2015;418(Pt 3):220–34.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rasha F, Sharma M, Pruitt K. Mechanisms of endocrine therapy resistance in breast cancer. Mol Cell Endocrinol. 2021;532: 111322.

    CAS 
    PubMed 

    Google Scholar 

  • Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. Cancer. 2019;125:3714–28.

    PubMed 

    Google Scholar 

  • Saatci O, Huynh-Dam K-T, Sahin O. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J Mol Med. 2021;99:1691–710.

    CAS 
    PubMed 

    Google Scholar 

  • Haque MM, Desai KV. Pathways to Endocrine Therapy Resistance in Breast Cancer. Front Endocrinol. 2019;10:573.

    Google Scholar 

  • Hanker AB, Sudhan DR, Arteaga CL. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell. 2020;37:496–513.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An abridged explanation and elaboration. J Natl Cancer Inst. 2018;110:803–11.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, et al. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 2011;119:92–101.

    PubMed 

    Google Scholar 

  • Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023;34:645–59.

    CAS 
    PubMed 

    Google Scholar 

  • Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:105–13.

    CAS 
    PubMed 

    Google Scholar 

  • Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259–71.

    CAS 
    PubMed 

    Google Scholar 

  • BEA core facility. Bioinformatics and Expression Analysis. http://www.bea.ki.se/ (accessed 5 Mar2023).

  • Thermo Fisher Scientific Inc. Transcriptome Analysis Console (TAC) v4.0.3 User Guide. Affymetrix Inc., 2022https://www.thermofisher.com/content/dam/LifeTech/Documents/PDFs/TAC_v4.0.3_User_Guide.pdf (accessed 24 Oct2024).

  • Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267–73.

    CAS 
    PubMed 

    Google Scholar 

  • Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011; 27: 1739–1740.

  • Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417–25.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000;28(1):27. https://doi.org/10.1093/nar/28.1.27.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Milacic M, Beavers D, Conley P, Gong C, Gillespie M, Griss J, et al. The reactome pathway knowledgebase 2024. Nucleic Acids Res. 2024;52(D1):D672–8. https://doi.org/10.1093/nar/gkad1025.

  • The Broad Institute. GSEA User Guide. GSEA. 2004–2024. http://www.gsea-msigdb.org/gsea/doc/GSEAUserGuideFrame.html?_Interpreting_GSEA_Results (Accessed 24 Oct 2024).

  • Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rueda OM, Sammut S-J, Seoane JA, Chin S-F, Caswell-Jin JL, Callari M, et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature. 2019;567:399–404.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Bhuva D, Smyth G, Garnham A. msigdb: An ExperimentHub Package for the Molecular Signatures Database (MSigDB). R package version 1.14.0. 2024. https://davislaboratory.github.io/msigdb.

  • Zhao X, Rødland EA, Tibshirani R, Plevritis S. Molecular subtyping for clinically defined breast cancer subgroups. Breast Cancer Res. 2015;17:29.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–7.

    PubMed 
    PubMed Central 

    Google Scholar 

  • R Foundation for Statistical Computing, Vienna, Austria. R: A language and environment for statistical computing. https://www.R-project.org/.

  • Prat A, Lluch A, Turnbull AK, Dunbier AK, Calvo L, Albanell J, et al. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse. Clin Cancer Res. 2017;23:3035–44.

    CAS 
    PubMed 

    Google Scholar 

  • Pascual T, Fernandez-Martinez A, Tanioka M, Dieci MV, Pernas S, Gavila J, et al. Independent validation of the PAM50-based chemo-endocrine score (CES) in hormone receptor–positive HER2-positive breast cancer treated with neoadjuvant anti–HER2-based therapy. Clin Cancer Res. 2021;27:3116–25.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Microsoft Corporation. Microsoft® Excel® for Microsoft 365 MSO. Available from: https://office.microsoft.com/excel.

  • Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L et al. Updated Standardized Definitions for Efficacy End Points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0. J Clin Oncol 2021; 39: 2720–2731.

  • Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28: 1700–1712.

  • Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736–1747.

  • Yu NY, Iftimi A, Yau C, Tobin NP, van ’t Veer L, Hoadley KA et al. Assessment of long-term distant recurrence-free survival associated with tamoxifen therapy in postmenopausal patients with luminal A or luminal B breast cancer. JAMA Oncol 2019; 5: 1304–1309.

  • Ignatov A, Eggemann H, Burger E, Ignatov T. Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol. 2018;144:1347–55.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res. 2014;20:1298–305.

    CAS 
    PubMed 

    Google Scholar 

  • Clusan L, Ferrière F, Flouriot G, Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int J Mol Sci 2023; 24. https://doi.org/10.3390/ijms24076834.

  • Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87:905–31.

    CAS 
    PubMed 

    Google Scholar 

  • Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol. 2019;116:135–70.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Nardone A, De Angelis C, Trivedi MV, Osborne CK, Schiff R. The changing role of ER in endocrine resistance. Breast. 2015;24(Suppl 2):S60–6.

    PubMed 

    Google Scholar 

  • Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2010;126:545–62.

    CAS 
    PubMed 

    Google Scholar 

  • André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929–40.

    PubMed 

    Google Scholar 

  • Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.

    CAS 
    PubMed 

    Google Scholar 

  • Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, et al. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. J Clin Oncol. 2018;36:1556–63.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    CAS 
    PubMed 

    Google Scholar 

  • Wang X, Sun Z, Zimmermann MT, Bugrim A, Kocher J-P. Predict drug sensitivity of cancer cells with pathway activity inference. BMC Med Genomics. 2019;12:15.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Belachew EB, Sewasew DT. Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer. Front Endocrinol. 2021;12: 599586.

    Google Scholar 

  • Harvell DME, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, et al. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008;112:475–88.

    CAS 
    PubMed 

    Google Scholar 

  • Liang X, Briaux A, Becette V, Benoist C, Boulai A, Chemlali W, et al. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609). J Hematol Oncol. 2018;11:124.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Matsuyama R et al. G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer. Int J Mol Sci 2020; 21. https://doi.org/10.3390/ijms21082921.

  • Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Nagahashi M et al. The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer. Cells 2020; 9. https://doi.org/10.3390/cells9071643.

  • Shen W-J, Zhang Y. RPN1 promotes the proliferation and invasion of breast cancer cells by activating the PI3K/AKT/mTOR signaling pathway. Discov Oncol. 2024;15:25.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Althobiti M, El-Sharawy KA, Joseph C, Aleskandarany M, Toss MS, Green AR, et al. Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer. Breast Cancer Res Treat. 2021;189:621–30.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Oshi M, Tokumaru Y, Angarita FA, Yan L, Matsuyama R, Endo I et al. Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer. Cancers 2020; 12. https://doi.org/10.3390/cancers12123557.

  • Takeshita T, Tokumaru Y, Oshi M, Wu R, Patel A, Tian W, et al. Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment. Front Oncol. 2022;12: 865024.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Elfaki I, Mir R, Almutairi FM, Duhier FMA. Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis. Asian Pac J Cancer Prev. 2018;19:2057–70.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Schroth W, Mürdter TE, Schwab M. Unraveling the impact of drug metabolism on tamoxifen response in breast cancer. Cancer Epidemiol Biomarkers Prev. 2025;34(2):221–3.

    CAS 
    PubMed 

    Google Scholar 

  • Bergers G, Fendt SM. The metabolism of cancer cells during metastasis. Nat Rev Cancer. 2021;21(3):162–80.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A, et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA. Cytoscape and EnrichmentMap Nat Protoc. 2019;14(2):482–517.

    CAS 
    PubMed 

    Google Scholar 

  • Bull C, Byrne RM, Fisher NC, Corry SM, Amirkhah R, Edwards J, et al. Dual gene set enrichment analysis (dualGSEA); an R function that enables more robust biological discovery and pre-clinical model alignment from transcriptomics data. Sci Rep 2024 4;14(1):30202.

  • El-Botty R, Morriset L, Montaudon E, Tariq Z, Schnitzler A, Bacci M, et al. Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers. Nat Commun. 2023;14(1):4221.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Wimmer I, Tröscher AR, Brunner F, Rubino SJ, Bien CG, Weiner HL, et al. Systematic evaluation of RNA quality, microarray data reliability and pathway analysis in fresh, fresh frozen and formalin-fixed paraffin-embedded tissue samples. Sci Rep. 2018;8:6351.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1–2):373-386.e10.

    CAS 
    PubMed 

    Google Scholar 

Continue Reading

  • Banks that don’t meet recapitalisation target will downgrade their licences – Yemi Cardoso

    Banks that don’t meet recapitalisation target will downgrade their licences – Yemi Cardoso

    This article was produced with the support of Central Bank of Nigeria

    Cardoso made the clarification during a fireside chat on Friday, 10 October 2025, with Professor Helene Rey, Lord Bagri Professor of Economics at the Wheeler Institute of Business and Development, London Business School. The discussion, held in London with investors, academics, students and media representatives, came ahead of the IMF/World Bank Annual Meetings taking place from 13–18 October in Washington, DC.

    Responding to a question from African Business, the CBN Governor said the recapitalisation exercise, which will conclude at the end of March 2026, is aimed at ensuring Nigeria maintains strong and resilient banks.

    “With the banking recapitalisation, we left the door open in terms of the category of banking licence you decide to adopt,” Cardoso said. “If you feel that you cannot meet your capital requirement, you can downgrade your licence and move into another category of banks. You don’t need to merge if you don’t have to—but if you want to merge, go ahead.

    I must emphasise that we have given all banks enough time to ensure they are able to meet the category of licence they want to hold. So we don’t see any cause for panic or disruption. Many of these anxieties may come from legacy issues—things that happened in the past that didn’t turn out well. We have given all banks different options. As these categories begin to emerge, you need to decide where your strengths lie and focus on that. You can’t be all things to all people.”

    Earlier in the conversation, Cardoso clarified his comments on the CBN’s goal of achieving single-digit inflation, following the World Bank’s latest Africa’s Pulse report which described the target as unrealistic. The report projected that Nigeria, alongside Angola, Ethiopia, Ghana, Malawi, Sudan, Zambia, São Tomé and Príncipe, and Zimbabwe, will continue to record double-digit inflation throughout 2025.

    “Sometimes one gets misquoted. I was clear that this is our goal in the medium term—that’s what I said,” he explained. “And you know why I said that? We have to challenge ourselves as Nigerians. We cannot be saying it’s alright to have double-digit inflation. We’ve got to keep pushing ourselves to get there.”

    Cardoso also emphasised the need for better coordination between monetary and fiscal policy to sustain recent gains.

    “This has been a challenge for Nigeria for years,” he said. “But the difference today is that the reforms that have taken place at the central bank are judged to be relatively successful, and people can feel the impact. That is encouraging the fiscal side to say, ‘Okay guys!’—and that’s a good thing.”

    On the naira, Cardoso said that despite its earlier devaluation, the currency has now found its true value and become competitive under the market-determined, willing-buyer–willing-seller regime.

    According to him, the market has responded positively to ongoing reforms, with the gap between the official and parallel market rates narrowing from about 50% to less than 2%. He added that there has been an accretion in reserves, a rise in foreign portfolio investments, and an improved ability of the CBN to meet domestic demand for foreign exchange.

    “Nigerians are comfortable with the fact that even though the naira was devalued, it is now stable and there is predictability, allowing people to plan,” he concluded. “Without stability, we can’t have meaningful progress.”

    Continue Reading

  • Écija: AI, external capital and expansion in Latin America

    Écija: AI, external capital and expansion in Latin America

    102.3 million in 2024, 37 offices and a £200 million target by 2030: Écija’s rise amid AI and investors

    by mercedes galán

    The legal sector is experiencing a moment of accelerated transformation, driven by digitalization, artificial intelligence and the entry of external capital in some firms. In this context, Hugo Écija, founder and chairman of Écija Abogados, sets out his model: business structure with separation between capital, management and service provision, intensive adoption of technology and an internal culture oriented towards continuous adaptation.

    “I started my firm at 26, and today I am 53. I have dedicated more than half of my life to this project, which has been vital, with vision and always evolving,” recalls Écija, who founded his firm in Madrid in 1997.

    ORIGIN
    With the start of the new century, Écija decided to structure the firm as a limited company, separating capital, management and service provision, and focused on then-emerging areas such as audiovisual law and intellectual property. “Lawyers were at once owners, managers and those who contributed capital. Everything was mixed. I came from doing an MBA, from working in the U.S., and I asked myself: why did lawyers have to do everything?” he explains.
    That business approach, unusual in Spanish legal practice in the late 1990s, made a difference. “Innovation is not only technological: law firms are companies that must adapt to the social, cultural and technological environment. Those that do not, die. And the speed of adaptation today is vital,” he comments.

    ARTIFICIAL INTELLIGENCE

    …

    Continue Reading

  • 4th ASEAN+3 Economic Cooperation and Financial Stability Forum (AMRO Forum) – ASEAN+3 Macroeconomic Research Office

    4th ASEAN+3 Economic Cooperation and Financial Stability Forum (AMRO Forum) – ASEAN+3 Macroeconomic Research Office

    The ASEAN+3 Economic Cooperation and Financial Stability Forum, or AMRO Forum, is a platform for regional and global exchange of knowledge and ideas on economic cooperation and financial stability.

    In its fourth edition, AMRO will co-organize the forum with the Hong Kong Monetary Authority (HKMA) and Bank for International Settlements (BIS), with a common goal of achieving macroeconomic and financial resilience and stability for the region.

    This year’s theme is Fragmentation to Resilience: Macro-financial Stability and Regional Integration in ASEAN+3. The ASEAN+3 region is faced with challenge of safeguarding financial stability and strengthening macro-financial resilience while sustaining long-term prosperity. Although ASEAN+3 has made substantial progress in economic and financial cooperation over recent decades, the current global transformation demands even higher degree of collective action to navigate the changing international order.

    The forum will discuss the near-term risks and challenges to the region’s macro-financial stability and outlook, and present solutions and initiatives to promote its medium to long-term economic growth journey. There will be two sessions, comprising keynote speeches and panel discussions.

    Join us online on November 25, 2025!

    REGISTER NOW


    Continue Reading

  • BA stalls over paying out £220 flight compensation | Money

    BA stalls over paying out £220 flight compensation | Money

    I booked a Tui river cruise package in Switzerland with flights provided by British Airways.

    On the day we were to return home, we discovered our flight had been cancelled. There were about 40 people affected.

    BA eventually booked us on to a flight leaving 36 hours later, but has refused to pay us the £220 compensation each due under EC regulations.

    It says adverse weather was to blame and is exempted from compensation rules.

    I requested a formal confirmation of the cancellation to submit to my travel insurer and, on that form, BA claims “operational reasons” were the cause. Unlike adverse weather, this is not covered by the insurance policy.

    AC, Alfreton, Derbyshire

    This is outrageous behaviour from a company that once considered itself “the world’s favourite airline”. You can’t get compensation from BA because, it says, bad weather grounded the flight, and you can’t get compensation from the insurer because the airline claims it was an operational issue.

    The difference is critical. Airlines are obliged to pay set sums of compensation for delayed or cancelled flights under regulation EC 261/2004. They can only get out of it if the disruption was caused by “extraordinary circumstances”.

    The regulation is vague on what these circumstances might be, but years of court rulings have honed the list down. Undefined “operational issues” would not be considered an excuse to avoid a payout; weather sometimes is, but only if it is exceptional and unexpected.

    So which was the cause? Both, says BA, hedging its bets. It claims bad weather that had disrupted previous flights had displaced crew, and that had had a knock-on effect on your journey.

    It ignored my questions about the whens, wheres and hows but that’s immaterial. “Knock-on” effects of bad weather are not an excuse to withhold compensation, according to the law firm Bott & Co.

    BA insisted it couldn’t comment further because, by then, your case was in the hands of its dispute resolution service, CEDR.

    This sounded to me like stalling tactics. I pointed this out and suddenly it stumped up. Since the money had to be prised out of it, I fear the other affected passengers may still be empty-handed.

    We welcome letters but cannot answer individually. Email us at consumer.champions@theguardian.com or write to Consumer Champions, Money, the Guardian, 90 York Way, London N1 9GU. Please include a daytime phone number. Submission and publication of all letters is subject to our terms and conditions.

    Continue Reading

  • Fairfax Sells Eurolife Life Insurance Business Stake to Eurobank for $945 Million

    Fairfax Sells Eurolife Life Insurance Business Stake to Eurobank for $945 Million

    By Maitane Sardon 

    
   Fairfax Financial said it agreed to sell its 80% stake in the insurance business of Eurolife FFH Insurance Group to Eurobank Ergasias for 813 million euros ($944.7 million) in cash. 
    

    
  As part of the deal, Fairfax  will buy a 45% stake in ERB Asfalistiki--Eurobank's Cyprus-based property and casualty insurance business--for 59 million euros in cash, the Canadian insurance company said Monday. It will have the right to acquire the remaining 55% equity interest in ERBA over time, it said. 
    

    
  Following the transaction, Fairfax will keep its 80% stake in Eurolife's property and casualty insurance business, while Eurobank will fully own Eurolife's life insurance operations. 
    

    
  "We are very pleased to be able to maintain the focus of our insurance operations on property and casualty insurance and reinsurance, while still benefiting from the continued success of the Eurolife life insurance business through our ownership stake in Eurobank," Fairfax Chief executive Officer Prem Watsa said. 
    

    
  The deal is expected to close in the first quarter of 2026, Fairfax said. 
    

    
  Write to Maitane Sardon at maitane.sardon@wsj.com 
    

    
  (END) Dow Jones Newswires
    

    
  October 13, 2025 02:59 ET (06:59 GMT)
    

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading

  • Transforming Parenting E-Commerce Supply Chains

    Transforming Parenting E-Commerce Supply Chains


    Case studies


    Summary: By staying closely engaged with a fast-growing e-commerce brand, Maersk identified evolving supply chain gaps and helped streamline operations under one roof.




    Understanding a customer’s evolving needs starts with asking the right questions and staying closely engaged. For Maersk, working with fast-growing e-commerce brand specialising in mother and baby products, meant staying closely aligned with their evolving supply chain challenges. By keeping the conversation open and ongoing, we were able to spot gaps in their supply chain and find practical ways to simplify, streamline, and bring everything under one roof.

    How it started

    As an existing Warehousing and Distribution (WnD) customer of Maersk, the company was looking to streamline operations at the origin by better managing suppliers and gaining improved visibility over shipments. A qualification discussion highlighted a broader opportunity: strengthening their overall Supply Chain Management (SCM).

    During the Internet Summit, the customer was introduced to our Container Freight Station (CFS) solution, which sparked strong interest. This led to a series of focused discussions with their logistics team to assess the potential value of integrating SCM and CFS into a consolidated approach.

    Maersk stepped in as more than a logistics provider, offering end-to-end supply chain solutions that bring together logistics, fulfillment, and value-added services in one integrated platform.

    Challenges at a glance

    The customer faced several challenges across their supply chain that were impacting efficiency and visibility. Key issues included a reliance on cumbersome manual processes and limited visibility into shipments at the SKU or product level, making it difficult to track inventory and plan effectively.

    Uncertainty around shipment arrivals further complicated operations, while the use of Less-than-Container Load (LCL) shipments presented missed opportunities for cost-saving through consolidation into Full Container Loads (FCL). Additionally, having too many stakeholders involved created coordination hurdles, with manual follow-ups and milestone tracking adding to the complexity and operational strain.




















    Current challenges
    Maersk solutions


    Current challenges


    SKU & Product level


    Maersk solutions


    PO & Shipment management


    Current challenges


    Shipper performance


    Maersk solutions


    Vendor management


    Current challenges


    Insights for decision making


    Maersk solutions


    Performance management & reporting


    Current challenges


    Allocation fulfillment


    Maersk solutions


    Carrier management


    Current challenges


    Coordination with suppliers and forwarders


    Maersk solutions


    End-to-end management


    Current challenges


    Tracking of milestone


    Maersk solutions


    Shipment management


    Current challenges


    Operational fire fighting


    Maersk solutions


    Strategic supply chain management 

    Transition to a comprehensive solution

    We transitioned from a single-solution approach to a more comprehensive one-stop solution (integrator strategy) by asking the right questions and mapping out the end-to-end process to identify gaps and opportunities.

    By involving the appropriate stakeholders from Maersk to co-design the solution and present it to the customer, demonstrating our deep supply chain expertise and operational know-how.


    The key to lasting partnerships is to treat the customer’s business as if it were your own—because their success is ultimately ours too.


    Sherylyn Pondiong

    Business Development Manager, Integrated Sales, Retail & Lifestyle, A.P. Moller – Maersk


    Our value proposition

    Our value proposition played a pivotal role in reinforcing trust and aligning strategic priorities with the customer’s long-term goals. Specifically, the solution delivered impact in the following key areas:



    Executive alignment & strategic insight


    By engaging directly with the customer’s senior leadership, our value proposition ensured there was a clear alignment between our service capabilities and the customer’s evolving business strategy. This elevated the relationship beyond a transactional level to a true strategic partnership.



    Tailored solutions & decision-making support

    Leveraging their deep industry knowledge and experience, we offered tailored recommendations that addressed the customer’s pain points—particularly around supply chain efficiency, cost optimisation, or scaling operations. This proactive approach demonstrated our commitment to their success and helped influence faster, more confident decision-making on their end.



    Escalation ownership & risk mitigation


    Maersk took ownership of key escalations, ensuring rapid resolution of issues while minimising operational disruptions. This hands-on leadership strengthened the customer’s confidence in our responsiveness and governance model.



    Future-ready planning


    Through forward-looking discussions, we helped the customer identify upcoming market trends and prepare their operations accordingly. This included introducing innovative service options or potential areas of automation, digitalisation, or sustainability initiatives.

    Driving measurable improvements

    Our customer saw value in having one Logistics Service Provider (LSP) handle end-to-end solutions, including SCM (CY and CFS consolidation), ocean freight, CHB, and trucking, providing a ‘one source of truth’ for them and internal stakeholders.

    The volume awarded was 26,000 cubic meters, with a total revenue of USD 250K over a contract duration of 2 years.



    Strengthening what comes next

    Building on the success of the initial collaboration, we are now focused on expanding the partnership through several strategic initiatives. Phase 2 CFS implementation is underway in Qingdao and Yantian, with further opportunities being explored in Turkey and the UK.

    A long-term ocean freight contract is being developed to ensure stability, while Customs House Brokerage and SABER verification are being set up to support smooth imports into Saudi Arabia. Cross-border trucking from the UAE to KSA is also being introduced, marking continued progress toward a more integrated, streamlined and resilient supply chain.

    Continue Reading

  • HENSOLDT and AVILUS join forces for innovative UAV solutions “Made in Germany”

    HENSOLDT and AVILUS join forces for innovative UAV solutions “Made in Germany”

    The integration of powerful HENSOLDT sensors – including a high-performance electro-optical system, AMPS-M and the ‘PrecISR’ radar – with the innovative ‘MissMarvin’ mission operating system will result in scalable UAV platforms that meet both military and civilian requirements.

    “With AVILUS, we have an agile UAV specialist at our side who can optimally leverage our state-of-the-art sensor solutions. Together, we are focusing on technological sovereignty and short paths from development to operational readiness – for powerful and resilient UAV expertise in Germany,” says Christina Canitz, Head of Division Optronics at HENSOLDT.

    “AVILUS closes specific capability gaps in casualty evacuation, logistics and reconnaissance with robust, unmanned aerial systems. The focus is on operational proximity, reliability and rapid availability. Through close cooperation with HENSOLDT, we combine our platforms with state-of-the-art sensor technology, thus creating immediate added value for forces in the field,” says AVILUS CEO Ernst Rittinghaus.

    The electro-optical system enables the detection, classification and tracking of objects thanks to multispectral sensor technology and AI-supported real-time processing. It combines HD thermal imaging, colour/low-light, SWIR and wide-angle cameras for comprehensive situation assessment – all sensors are available simultaneously and can be controlled via a high-precision 4-axis gimbal.

    AMPS-M combines a self-protection system with up to 16 intelligent decoy launchers and integrates various warning sensors and protective measures against missile, laser and radar threats. The platform benefits from high modularity, minimal maintenance and more than 700 systems in use worldwide with thousands of flight hours – tested in cooperation with NATO partners.

    PrecISR, a software-defined X-band radar with active electronically scanned array (AESA), detects and tracks more than 1,000 objects simultaneously, including ground, sea and air targets, regardless of weather conditions and at great distances. The system is easy to integrate, ITAR-free and, thanks to its scalability, suitable for a wide range of UAV platforms.

    With the Federal Aviation Authority’s approval for civil flights already granted and the ‘company owned, company operated’ operating model, the partners are addressing a wide range of application scenarios – from disaster control and critical infrastructure monitoring to national border security.

    The cooperation is part of HENSOLDT’s strategy to create innovative solutions in line with ‘software-defined defence’ through targeted partnerships. Initial demonstrations and pilot projects are already in preparation. The aim is to set new standards for ISR capabilities in unmanned aviation, both nationally and internationally.

    Continue Reading

  • The request could not be satisfied


    ERROR: The request could not be satisfied

    The request could not be satisfied.

    Request blocked.
    We can’t connect to the server for this app or website at this time. There might be too much traffic or a configuration error. Try again later, or contact the app or website owner.


    If you provide content to customers through CloudFront, you can find steps to troubleshoot and help prevent this error by reviewing the CloudFront documentation.

    Generated by cloudfront (CloudFront)
Request ID: n7HORFqvpoHj5CstwRmH6REuvJVNwzl6qy1RK1wjzWgpwC_3Da4gfQ==

    Continue Reading

  • Warburg Pincus to Acquire PSI Software for Over $800 Million

    Warburg Pincus to Acquire PSI Software for Over $800 Million

    By Billy Gray 

    
  PSI Software agreed to be acquired by private-equity group Warburg Pincus in a deal valued at over 700 million euros ($813.4 million). 
    

    
  The companies signed a deal under which the U.S.-based Warburg Pincus will launch a voluntary public takeover offer for all outstanding shares of the German software-solutions group at 45 euros a share in cash, the companies said Monday. PSI currently has 15.7 million outstanding shares, according to its website. 
    

    
  As part of the agreement, Warburg Pincus signed share-purchase agreements and irrevocable undertakings with PSI shareholders that own about 28.5% of the company's total share capital, the companies said. One anchor shareholder will reinvest parts of its proceeds alongside Warburg Pincus into the holding structure, they added. 
    

    
  German utility E.ON, the second largest PSI shareholder and a customer of the software company, will retain its 17.77% stake, PSI said. It will also act jointly with Warburg Pincus on the deal. 
    

    
  PSI said Warburg Pincus will support its current growth strategy, maintain the existing management team and protect employee roles. The group said its headquarters will remain in Berlin, and that neither party would enter into a domination or profit and loss transfer deal for two years after closing the offer, which is expected in the first half of 2026. 
    

    
  Write to Billy Gray at william.gray@wsj.com 
    

    
  (END) Dow Jones Newswires
    

    
  October 13, 2025 02:20 ET (06:20 GMT)
    

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading